2-5A antisense treatment of respiratory syncytial virus.
Although a prominent cause of upper and lower respiratory tract disease in infants and the elderly, clinical options for treatment of respiratory syncytial virus (RSV) infections remain limited. Historically, attempts to develop vaccines have been unsuccessful, and rapid viral mutation rates have stifled development of several small molecule-based antiviral agents. Thus, targeted approaches to block RSV replication, including humanized monoclonal antibodies and nucleic acid-based strategies (antisense and RNA interference), have emerged as potentially viable drug development options.
Leaman
Douglas W
DW
Department of Biological Sciences, University of Toledo, Toledo, Ohio 43606, USA. dleaman@utnet.utoledo.edu
D000227:Adenine Nucleotides / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D009843:Oligoribonucleotides / Q000494:pharmacology* / Q000627:therapeutic use*; D020320:Oligoribonucleotides, Antisense / Q000494:pharmacology* / Q000627:therapeutic use*; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000517:prevention & control / Q000821:virology; D012136:Respiratory Syncytial Viruses / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D014779:Virus Replication / Q000187:drug effects
D000227:Adenine Nucleotides; D009843:Oligoribonucleotides; D020320:Oligoribonucleotides, Antisense; C023505:2',5'-oligoadenylate